Verquvo mechanism of action?

How Verquvo works (mechanism of action)

Verquvo (vericiguat) is a medicine for chronic heart failure. Its mechanism of action targets the nitric oxide (NO)–soluble guanylate cyclase (sGC) signaling pathway. Vericiguat directly stimulates soluble guanylate cyclase, which increases intracellular cyclic GMP (cGMP) levels. Higher cGMP then helps promote vasodilation and improves heart and blood-vessel function in people with heart failure by enhancing downstream signaling involved in the NO–cGMP pathway [1].

Why targeting the NO–cGMP pathway matters in heart failure

In chronic heart failure, signaling through the NO–sGC–cGMP pathway can be reduced, contributing to worse vascular tone and impaired cardiovascular function. By boosting this pathway via direct sGC stimulation, vericiguat aims to counter those abnormalities and support more favorable hemodynamics and cardiac function [1].

What downstream effects cGMP activation is linked to

By increasing cGMP, the drug promotes effects tied to that signaling cascade, including improved vascular relaxation (vasodilation). Those changes support the cardiovascular goals of heart failure therapy—reducing strain on the heart and improving how blood vessels respond [1].

Safety and clinical relevance questions people often ask

Patients and clinicians commonly ask about how a drug that raises cGMP might affect blood pressure or fluid balance. Because vericiguat increases cGMP signaling (which is associated with vasodilation), hypotension is a known class-related concern that is typically monitored in practice for therapies that influence this pathway [1].

Sources

1. https://www.drugs.com/verquvo.html